# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-Reuters
Sanofi's phase 3 IMROZ study shows Sarclisa with VRd significantly improves progression-free survival in newly diagnosed, t...
GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (rani...
https://group.dhl.com/en/media-relations/press-releases/2024/dhl-supply-chain-expands-pharma-logistics-operations-in-france.html
The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 202...
Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COP...
The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the sup...